Evaluating a new PET imaging method for staging blood cancers
[68Ga]Pentixafor PET/CT for Staging of Hematological Malignancies: Comparison to [18F]FDG PET/CT
This study is testing a new PET imaging method to see if it can better stage blood cancers like non-Hodgkin's lymphoma and myeloma compared to the standard imaging technique.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Xijing Hospital Academic / other |
| Locations | 1 site (Xi'an, Shaanxi) |
| Trial ID | NCT06834412 on ClinicalTrials.gov |
What this trial studies
This clinical study aims to assess the effectiveness of 68Ga-Pentixafor PET imaging compared to the standard 18F-FDG PET/CT imaging in staging hematological malignancies, specifically non-Hodgkin's lymphoma and myeloma. A total of 120 patients aged 18 to 75 with confirmed diagnoses will participate in this prospective, open-label study. Each participant will undergo both imaging techniques to determine if the new method can provide reliable information for clinical staging and treatment response evaluation.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 with a confirmed diagnosis of non-Hodgkin's lymphoma or myeloma.
Not a fit: Patients who are children, pregnant or lactating women, or those with severely impaired liver or kidney function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of staging and treatment monitoring for patients with hematological malignancies.
How similar studies have performed: While the use of PET imaging in hematological malignancies is established, the specific application of 68Ga-Pentixafor PET imaging is relatively novel and has not been extensively tested in this context.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Ages 18 to 75 years old Confirmed by pathology with NHLs or myeloma Willing and able to follow the study protocol. Exclusion Criteria: Children, pregnant or lactating women Severely impaired liver and kidney function (alanine aminotransferase \> 8-10 times the upper limit of normal, serum creatinine 186-442 umol/L) With a history of allergy to contrast media or other drugs
Where this trial is running
Xi'an, Shaanxi
- Department ofNuclear Medicine,Xijing Hospital, Fourth Military Medical University — Xi'an, Shaanxi, China (Recruiting)
Study contacts
- Study coordinator: Ying Guo
- Email: guoying01192022@163.com
- Phone: 0086+15991459177
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.